Journal of Cellular Physiology

Characterization of Notch signaling during osteogenic differentiation in human osteosarcoma cell line MG63

Journal:	*Journal of Cellular Physiology*
Manuscript ID:	JCP-15-0369
Wiley - Manuscript type:	Original Research Article
Date Submitted by the Author:	14-Jul-2015
Complete List of Authors:	Ongaro, Alessia; University of Ferrara, Department of Morphology, Surgery and Experimental Medicine Pellati, Agnese; University of Ferrara, Department of Morphology, Surgery and Experimental Medicine Bagheri, Leila; University of Ferrara, Department of Morphology, Surgery and Experimental Medicine Rizzo, Paola; University of Ferrara, Department of Morphology, Surgery and Experimental Medicine Caliceti, Cristiana; University of Ferrara, Department of Medical Sciences and Laboratory for Technologies of Advanced Therapies Massari, Leo; University of Ferrara, Department of Morphology, Surgery and Experimental Medicine De Mattei, Monica; University of Ferrara, Department of Morphology, Surgery and Experimental Medicine
Key Words:	osteogenic differentiation, Notch, Hey1, BMP, MG63

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Characterization of Notch signaling during osteogenic differentiation in human osteosarcoma cell line MG63

Alessia Ongaro[1*] PhD, Agnese Pellati[1] BS, Leila Bagheri[1] MS, Paola Rizzo[1] PhD, Cristiana Caliceti[2] PhD, Leo Massari[1] MD, Monica De Mattei[1] PhD

[1]*Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy;*

[2]*Department of Medical Sciences and Laboratory for Technologies of Advanced Therapies, University of Ferrara, Ferrara, Italy*

***Corresponding author: Alessia Ongaro**

Department of Morphology, Surgery and Experimental Medicine, Section of Anatomy and Histology, University of Ferrara,

Via Fossato di Mortara 64/B

44121 Ferrara, Italy

Tel: +39 0532 455564

Fax: +39 0532 455533

e-mail: alessia.ongaro@unife.it

Running Head: Notch signaling in osteogenic differentiation

Key words: osteogenic differentiation, Notch, Hey1, BMP, MG63.

Total number of text figures: 7

Contract grant sponsor: This work was supported in part by IGEA S.p.A (Carpi, Italy)

For Peer Review

ABSTRACT

Osteogenic differentiation is a multi-step process controlled by a complex molecular framework. Notch is an evolutionarily conserved intercellular signaling pathway playing a prominent role in cell fate and differentiation, although the mechanisms by which this pathway regulates osteogenesis remain controversial.

This study aimed to investigate *in vitro* the involvement of Notch pathway during all the developmental stages of osteogenic differentiation in human osteosarcoma cell line MG63. Cells were cultured in basal condition (control) and in osteoinductive medium (OM). The γ-secretase inhibitor DAPT was also added in OM to block Notch pathway.

During osteogenic differentiation, early (alkaline phosphatase activity and collagene type I) and late osteogenic markers (osteocalcin levels and matrix mineralization), as well as the gene expression of the main osteogenic transcription factors (Runx2, Osterix and Dlx5) increased. Time dependent changes in the expression of specific Notch receptors were identified in OM versus control with a significant reduction in the expression of Notch1 and Notch3 receptors in the early phase of differentiation, and an increase of Notch2 and Notch4 receptors in the late phase. Among Notch nuclear target genes, Hey1 expression was significantly higher in OM than control, whilst Hes5 expression decreased. In DAPT, osteogenic markers were reduced and Hey1 was significantly inhibited, suggesting a role for Notch through the canonical pathway.

In conclusion, Notch pathway might be involved with a dual role in osteogenesis of MG63, through the activation of Notch2, Notch4 and Hey1, inducing osteoblast formation and the depression of Notch1, Notch3 and Hes5, maintaining an undifferentiated status.

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Osteoblast differentiation is a multi-step process where mesenchymal cells acquire the ability to deposit the mineralized extracellular matrix characteristic of bone tissue (Ducy et al., 2000). Significant progress has been made over the past decade in the understanding of the molecular framework that controls osteogenic differentiation. A large number of morphogens, signaling pathways, and transcriptional regulators have been implicated in regulating bone development, including Wnt/β-catenin, TGFβ/BMP, and Notch signaling pathways (Deng et al., 2008).

Notch pathway is an evolutionarily conserved intercellular signaling mechanism that plays a prominent role in cell fate decision during development and maintenance of homeostasis in adults (Bray, 2006). The canonical Notch pathway is activated when Notch receptors (Notch-1, -2, -3, and -4) interact with ligands [Jagged-1 and -2 and Delta-like (Dll-1, -3, and -4)] on adjacent cells, triggering two proteolytic cleavages of the receptor, the last one being performed by the presenilin–γ-secretase complex (Bray, 2006). Notch receptor activation releases the Notch intracellular domain (NICD), which translocates to the nucleus and activates transcription of Hes (hairy/enhancer of split) and Hey (Hes-related proteins) gene family members. Hes and Hey proteins are basic helix-loop-helix transcriptional regulators including the isoforms of Hes (HES-1, -3, and -5) and Hey (HEY-1, -2, and -3) (Iso et al., 2003).

Among the currently identified signaling molecules that play an important role in osteogenic differentiation, it has been reported a role for Notch signaling, although the mechanisms by which this pathway regulates osteogenesis are poorly understood (Deng et al., 2008; Sciaudone et al., 2003; Tezuka et al., 2002). Osteogenic differentiation proceeds through different developmental stages which are characterized by specific markers including early

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

markers such as alkaline phosphatase (ALP), collagen type I and late markers such as osteocalcin and mineralization. Further, several transcriptional factors have been identified as important regulators of osteogenic lineage commitment and terminal differentiation. These factors include Runt-related transcription factor 2 (Runx2), a master regulator of osteoblast differentiation and chondrogenesis (Komori, 2010) and Osterix, a zinc-finger-containing transcription factor that is essential for bone development and appears to act downstream of Runx2 in osteogenic differentiation (Nakashima et al., 2002). It is known that also other transcription factors including Dlx5 are involved and regulate ostegenic differentiation (Komori, 2006).

It remains controversial whether Notch signaling acts as a positive or negative regulator of osteogenic differentiation in osteoblast progenitor cells. It has been reported that overexpression of Hes-1 or Hey-1 enhances osteogenic differentiation of mesenchymal stem cells (Sharff et al., 2009) in part through positive regulation of and cooperation with Runx2, suggesting that Notch signaling may play positive roles in bone formation. On the other hand, presenilin-2 null mice have greatly increased trabecular bone mass, and Hey1 was shown to inhibit Runx2 transcriptional activity in mouse MC3T3 and C2C12 cells, suggesting the negative role of Notch signaling in osteogenesis (Zamurovic et al., 2004). Also, very few studies have investigated the role of specific Notch receptor on osteogenic differentiation and there are controversial data about Notch1 receptor (Deregowski et al., 2006; Shimizu et al., 2009; Tezuka et al., 2002). Therefore, further examination of the role of Notch signaling in regulating osteogenesis and bone formation is required.

To date no study has characterized the Notch pathway during all the developmental stages of osteogenic differentiation including proliferation, extracellular matrix synthesis, and mineralization.

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The aim of this study was to investigate *in vitro* the involvement of Notch pathway during all the phases of osteogenic differentiation in human osteosarcoma cell line MG63. MG63 cells were chosen because they have been well characterized as immature osteoblasts and have been applied as a tool for studying differentiation processes (Kraus et al., 2012). In order to study the role of Notch signaling during osteogenic differentiation, MG63 were cultured in basal condition and in osteoinductive medium. DAPT, which inhibits the γ-secretase responsible for intramembranous cleavage of Notch receptors and prevents the formation of NICD active form, was also used in order to confirm the involvement of Notch pathway during osteogenic differentiation. To our purpose, classical biochemical markers of osteogenic differentiation such as ALP activity, osteocalcin levels and mineralized bone nodules as well as the gene expression of the main ostegenic transcription factors (including Runx2, Osterix and Dlx5) and of the osteogenic gene collagene type I (Coll I), were analyzed to verify the behavior of the cells in the three experimental conditions tested (basal condition, osteoinductive medium in the absence and in the presence of DAPT). The characterization of Notch pathway during osteogenic differentiation was done by evaluating, in all the conditions, gene expression of Notch receptors (Notch1, Notch 2, Notch3, Notch4), their ligands (Jagged1, Dll4) and nuclear target genes (Hey1, Hey2, Hes1, Hes5) at different time points. A better understanding of molecular mechanisms behind osteogenic differentiation would not only help us to identify pathogenic causes of bone and skeletal diseases but also lead to the development of targeted therapies for these diseases.

MATERIALS AND METHODS

Cell cultures

Human osteosarcoma cell lines, MG63 were purchased from the ATCC (American Type Culture Collection, by LGC Standards S.r.l Sesto S.Giovanni (MI) Italy). Cells were grown in

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

high glucose Dulbecco's modified Eagle's medium/Nutrient mixture F-12 (DMEM/F12) supplemented with 4 mM L-glutamine, 10% FBS, penicillin ($100 Uml^{-1}$) and streptomycin ($100\ \mu gml^{-1}$) (complete DMEM/F12) (all purchased by GIBCO Life Technologies, Monza, Italy).

All cells were grown in a humidified atmosphere containing 5% CO_2 at 37°C.

Osteogenic differentiation

Cells were seeded in 4-well plate (for ALP activity, osteocalcin and Alizarin Red staining assays), 96-well plate (for cell proliferation assay) or 35 mm diameter cell culture dishes (for RealTime-PCR) at 2×10^3 cells/cm^2 in Osteogenic Differentiation Medium (OM) (Lonza by Euroclone, Milano, Italy), for 28 days (Ongaro et al., 2014). Control cells were cultured in basal condition (i.e. complete DMEM/F12). Medium was changed twice per week. Samples were harvested at days 1, 3, 7, 14, 21 and 28 for assays.

Cell Proliferation

Cell proliferation was assessed by Prestoblue Cell Viability Reagent (Invitrogen by Life Technologies, Monza, Italy). PrestoBlue Cell Viability Reagent solution was added to each well for all experimental conditions, at days 1, 3, 7, 14, 21 and 28 followed by incubation for 1 h. The cell absorbance values were measured at a wavelength of 570 nm with the correction at 620 nm using Sunrise microplate reader (TECAN, Cernusco sul Naviglio Milano, Italy).

DAPT treatment

DAPT (LY-374973, Sigma Aldrich S.r.l., Milano, Italy) was added at the final concentration of 10 µM to MG63 cultured in OM (OM+DAPT) during the whole differentiation period.

Alkaline phosphatase (ALP) activity

At the time points investigated, MG63 were washed with PBS and lysed in non-denaturant conditions by using 0.1% Triton X 100 (Sigma-Aldrich) in double-distilled H_2O followed by three times freezing and thawing of the membrane fractions at -20°C/25°C. ALP activity was

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

determined by incubating cellular lysates at 37°C for 30 minute in the presence of 10 mM p-nitrophenylphosphate (Sigma-Aldrich) in alkaline buffer containing 100 mM diethanolamine and 0.5 mM MgCl2, pH 10.5 (Sigma-Aldrich). The reaction was stopped with 0.4 M NaOH and the absorbance of each sample was read at 405 nm with a Sunrise microplate reader. ALP activity was normalized to total protein quantity measured using the bicinchoninic acid assay, a protein assay reagent kit (QuantumProtein by Euroclone) according to the manufacturer's instructions. ALP activity was expressed as µMol/(min × g protein).

For Peer Review

Detection of osteocalcin levels by enzyme-linked immunosorbent assay (ELISA)

MG63 cells were washed three times with PBS. Then 0.5 M HCl solution was added to each well followed by incubation for 30 min at 37°C, and neutralized by 1 M NaOH. The extracts obtained from cell monolayer were analysed using commercial ELISA kit (Invitrogen by Life Technologies) which uses monoclonal antibodies directed against distinct epitopes of human osteocalcin. Osteocalcin levels were expressed as ng ostocalcin/mg protein.

Alizarin Red S staining

MG63 were washed in PBS and fixed in 4% formalin for 10 min. The formalin solution was removed and after washing with distilled water, an Alizarin Red S solution (1%) (Histo-Line Lab. S.r.l, Milano, Italy) was added for 5 min. Images were taken using a standard light microscope (Nikon Eclipse TE 2000-E microscope, Nikon Instruments Spa, Sesto Fiorentino (FI), Italy) equipped with a digital camera (DXM 1200F; Nikon Instruments Spa, Italy). Further, the mineralized substrates were quantified by using a solution of 20% methanol and 10% acetic acid (both from Sigma Aldrich) in water. After 15 minutes, liquid was transferred into cuvettes and the quantity of dissolved Alizarin red was measured by the spectrophotometer (Jenway 6305, Vetrotecnica, Padova, Italy) at a wavelength of 450 nm.

Real-Time PCR

1
2
3 For RNA extraction, MG63 were washed three times with Earle's Solution and total RNA
4
5 was extracted using commercially available kit (PureLink RNA minikit Invitrogen by Life
6
7 Technologies). RNA concentration and purity were determined by NanoDrop 2000
8
9 spectrophotometer (Thermo Scientific, Inc., MA, USA). 2 µg of total RNA were reverse
10
11 transcribed in a final volume of 20 µl using the SuperScript™ III First-Strand Synthesis
12
13 system for RT-PCR (Invitrogen by Life Technologies) and 50 ng of random hexamers. Then
14
15 32 ng of the cDNA mixture were amplified using PerfeCta SYBR Green SuperMix ROX kit
16
17 (Quanta Biosciences by VWR, Milano, Italy) according to the manufacturer's protocol in a
18
19 final volume of 20 µl. Real-time PCR was carried out for Notch1, Notch2, Notch3, Notch4,
20
21 Jagged1, Dll4, Hey1, Hey2, Hes1, Hes5, Runx2, Dlx5, Osterix, Coll I in the total 40 cycles of
22
23 amplification: 95 °C for 15 s and 60 °C for 1 min and examined on a 7500 Fast Real-Time
24
25 PCR system (Applied Biosystems, Life Technologies). A concentration of 500 nM of primers
26
27 (all from IDT Tema Ricerca, Bologna, Italy) was used. The sequences of primers used were
28
29 the following: Notch1: forward 5′-GTCAACGCCGTAGATGACC-3′, reverse 5′-
30
31 TTGTTAGCCCCGTTCTTCAG-3′, Notch2: forward5′-CAGGCACTCGGGGCCTACTCT-
32
33 3′, reverse 5′-AGCCAGGCAAGCGACAA-3′; Notch3:forward5′-
34
35 TGCGATCAGGACATCAATGAC-3′, reverse 5-CTCAGGCACTCATCCACATC-
36
37 3′;Notch4: forward 5′-CAACTGCCTCTGTCCTGATG-3′, reverse 5′-
38
39 GCTCTGCCTCACACTCTG-3′; Jagged1: forward 5′- GACTCATCAGCCGTGTCTCA-3′,
40
41 reverse 5′-TGGGGAACACTCACACTCAA-3′; Dll4: forward 5′-
42
43 GCGAGAAGAAAGTGGACAGG-3″, reverse 5′-ATTCTCCAGGTCATGGCAAG-3′;
44
45 Hey1: forward 5′-CCGAGATCCTGCAGATGACCGT-3′ reverse 5′-
46
47 AACGCGCAACTTCTGCCAGG-3′: Hey2: forward 5′-AAAAGGCGTCGGGATCG-3′,
48
49 reverse 5′-AGCTTTTTCTAACTTTGCAGATCC-3′; Hes1: forward 5′-
50
51 CGGACATTCTGGAAATGACA-3′, reverse 5′-CATTGATCTGGGTCATGCAG-3′; Hes5:
52
53
54
55
56
57
58
59
60

forward 5′-AAGCACAGCAAAGCCTTCGT-3″, reverse 5′-TGGAGCGTCAGGAACTGCAC-3′ (Caliceti et al., 2013; Rizzo et al., 2008); Runx2: forward 5′-AAGCTTGATGACTCTAAACC-3″, reverse 5′-TCTGTAATCTGACTCTGTCC-3′; Dlx5: forward 5′-GCATTACAGAGAAGGTTTCAG-3″, reverse 5′-TTTTCACCTGTGTTTGTGTC-3′; Osterix: forward 5′-TGAGGAGGAAGTTCACTATG-3″, reverse 5′-CATTAGTGCTTGTAAAGGGG-3′; Coll1A1: forward 5′-GCTATGATGAGAAATCAACCG-3″, reverse 5′-TCATCTCCATTCTTTCCAGG-3′; GUSB was used as reference gene (GUSB: forward 5′-CCCGCGGTCGTCATGTGGTC-3″, reverse 5′-GCCGGGAGGGGTCCAAGGAT-3′).

The data were calculated by the $2^{-\Delta\Delta Ct}$ formula and changes in gene expression levels were referred to the reference gene of control cells (grown in DMEM/F12) at day 1.

Western blotting

Western blot analysis was carried out to detect Notch1, Notch2, Notch3, Notch4 and β-actin at day 21, by using the corresponding antibodies. Antibodies to Notch1 (C-20) and Notch4 (H-225) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibody to Notch3 (ab23426) was from Abcam (Cambridge, UK). Antibody to cleaved Notch1, valine 1744 (4147) was from Cell Signaling Technology (Beverly, MA, USA). Notch2 antibody (clone C651.6DbHN) was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by The University of Iowa (Department of Biology, Iowa City, IA 52242). β -actin antibody was from Sigma Aldrich (St. Louis, MS, USA). Western blotting was performed as previously reported by Caliceti et al. (Caliceti et al., 2013).

Statistical Analysis

1
2
3 All the experiments (n=5) were performed in triplicate. Data were expressed as means ± SEM. Statistical differences between the mean were determined by Student's t test. P values < 0.05 were considered statistically significant.

The analysis of gene expression during osteogenic differentiation was done by comparing the fold changes obtained in OM versus Control and OM + DAPT versus OM, at the different time points investigated (1, 3, 7, 14, 21, 28 days), as reported in figure legends.

RESULTS

Biochemical results in MG63 cell line

The osteogenic biomarkers analyzed in MG63 during osteogenic differentiation indicated the capability of these cells to differentiate into mature osteoblasts as shown by the analysis of ALP activity, osteocalcin (OC) production and calcium salts deposition (Figure 1). Specifically, ALP activity significantly increased at day 7 and day 14 in OM versus control (Figure 1A). OC was detectable in our cultures in OM from day 14 and it increased significantly until day 28 when compared to control cells (Figure 1B). The matrix mineralization analyzed by Alizarin red staining confirmed a trend similar to OC, showing an increase of calcium deposits mainly at the end of the differentiation period (Figure 1C). To verify if the changes observed in OM were due to differences in cell number, we also tested cell proliferation both in control and in OM treated cells and we found no significant differences between the two groups of cells (Figure 1D).

Gene expression of osteogenic genes

The analysis of the expression of the osteogenic transcription factors showed that both Runx2 and Dlx5 significantly increased during the differentiation from day 7 to day 28 when their expression in OM was compared to control cells (grown in DMEM/F12 at day 1) (Figure 2A-B). Differently, the expression of Osterix was significantly increased only at day 7 in OM

For Peer Review

with respect to control (2.25 fold, p=0.008) (Figure 2C). In addition to osteogenic transcription factors, we investigated also Coll I, a matrix gene typically expressed in osteoblasts. Coll I was more expressed in OM than in control at all time-points (Figure 2D) with significant differences from day 3 until day 28.

Gene expression of NOTCH pathway genes

The analysis of Notch related genes showed different results among Notch receptors, ligands and nuclear target genes. As far as concerns Notch receptor genes, a significant reduction in the expression of Notch1 and Notch3 at day 7 and 14 and an increase of Notch2 and Notch4 at day 21 and 28 were found, when OM was compared versus control (Figure 3A-D). Differently, no significant changes in the expression of Notch ligands (Jagged1 and Delta-like4) were observed (data not shown). Among the Notch nuclear target genes investigated, during osteogenic differentiation significant variations were obtained for Hey1 and Hes5 comparing OM versus control (Figure 3E-F). Specifically, Hey1 expression was significantly higher in OM compared with control from day 7 until day 28, with a maximum increase at day 21 (7.60 fold, p<0.0001). Hes5 expression decreased during differentiation in OM respect to control with significant differences at day 14 (0.37 fold, p=0.025) and 21 (0.33 fold, p=0.011).

Effects of DAPT treatment

The presence of DAPT in OM had significant effects on osteogenic biomarkers and genes. In particular, DAPT decreased ALP activity at all the time points with significant reduction from day 14 until day 28 (Figure 4A). At the same time points, DAPT determined also a significant decrease in OC levels with a complete inhibition of OC production at day 14 and 21 during differentiation (Figure 4B). Similar results were obtained by Alizarin red staining as calcium deposits were reduced in the presence of DAPT. The reduction was more appreciable in the

For Peer Review

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

middle stage of differentiation (day 14 -21) as shown in Figure 4C, reporting the spectrophotometric measure of the dissolved Alizarin red staining. However, the reduction of osteogenic biomarkers found in the presence of DAPT was independent from the cell number because DAPT did not influence cell proliferation at any time point investigated (Figure 4D).

In the presence of DAPT also changes in the specific osteogenic transcription factors were observed (Figure 5). A reduction of Runx2 was found at all time-points, but with significant value only at day 28 (0.50 fold, p=0.014) (Figure 5A). Differently, DAPT influenced Dlx5 at the early stage of differentiation, decreasing significantly its expression at day 3 and day 7 (Figure 5B) and halved the expression of Osterix at the day 7 and 14 (Figure 5C). Also the expression of Coll I was reduced in the presence of DAPT in OM compared with OM alone, with significant decrease from day 3 until day 28 (Figure 5D).

Furthermore, as expected, when Notch pathway was blocked by DAPT, a significant reduction in Hey1 expression was observed at all the differentiation times lowering the Hey1 levels as in control (Figure 6), indicating that the activation of Hey1 occurred mainly by the canonical Notch signaling. No effect of DAPT on the mRNA expression of the other nuclear target genes investigated neither on Notch receptors and ligands was observed.

The effects of DAPT treatment on MG63 during osteogenic differentiation were verified also by Western blotting analysis of Notch receptors (Figure 7). The immunoblots reported in Figure 7 show the pattern of Notch receptors in lysates from MG63 cultured in OM in the absence and in the presence of DAPT at day 21, the time-point at which greater differences were observed in gene expression, at least for Notch2 and Notch4.

The results confirmed the presence of unprocessed full-length precursor product migrated at a molecular mass of ~ 200 KDa for Notch receptors (Figure 7). In addition, faster migrating products could be observed both in OM and in the presence of DAPT for all Notch receptors.

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

However, differences in the intensity of these bands, between cells treated or untreated with DAPT, were found only for Notch 2 and Notch 4, whilst no changes were observed for Notch1 and Notch3. Western blot analysis utilizing an antibody (C-20) directed against the C-terminus of the Notch1 protein, showed that under the conditions tested, DAPT did not modified the intensity of a ~ 110 KDa band which represents the transmembrane form of Notch 1 (TM) receptor (Caliceti et al., 2013) (Figure 7). Further, the antibody specific for Notch1 cleaved at valine 1744, the active form of Notch1, did not detect any band (data not shown), suggesting low steady-state levels of Notch1 under our experimental conditions, or an alternative γ-secretase cleavage site.

Notch2 immunoblotting of cell lysates showed, in addition to the full length Notch2 precursor, also the mature processed Notch2 trans-membrane and intracellular fragment (TMIC) of the ~90 KDa (Figure 7). The presence of DAPT in MG63 resulted in an accumulation of faster migrating product, similar to Notch2 extracellular truncation (N2EXT) cleavage fragments previously described (Groot et al., 2014). Groot et al., in fact, reported that the activation of Notch2 receptor by ligands results in a reduction of TMIC fragment and in the appearance of a faster migrating product that accumulated when γ-secretase activity was blocked using γ-secretase inhibitor. Accordingly, the comparison of our immunoblotting results in the presence and absence of DAPT suggests for Notch2 the accumulation of faster migrating product when cells were treated with DAPT suggesting an involvement of Notch2 receptor during osteogenic differentiation.

Similarly to what observed for Notch1, we did not find differences in the immunoblotting pattern for Notch3 transmembrane form in the absence or presence of DAPT (Figure 7).

As far as concerns Notch4, the immunoblotting of cell lysates with an antibody against the C-terminus of Notch4 protein permitted to detect a fragment of 64 KDa (Figure 7)

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

corresponding to the active form of Notch4 (N4ICD), as previously reported (Caliceti et al., 2013). The treatment with DAPT reduced the expression of Notch4 active form compared with the treatment with OM alone, suggesting an active role for this receptor during osteogenic differentiation of MG63.

DISCUSSION

The present study reveals several novel findings concerning the significant role of Notch signaling during osteogenic differentiation. In spite of previous *in vitro* and *in vivo* studies investigating the role of Notch pathway in osteogenic differentiation, however to date no definitive and clear conclusions can be driven (Chen et al., 2014). Studies reported that *in vivo* or *in vitro* overexpression of NICD suppresses osteoblastic differentiation and bone formation (Zanotti et al., 2008), however, some controversy on the effect of Notch pathway on osteoblastic maturation exists, and both inhibitory (Bai et al., 2008; Zamurovic et al., 2004) and stimulatory (Nobta et al., 2005; Tezuka et al., 2002) effects on osteoblast differentiation and function have been reported. On the other hand, most previous studies generally investigated the possible involvement of Notch pathway by experimentally inducing overexpression or loss of function in specific and single Notch receptors or Notch related genes and generally the effects were evaluated only in early phases of differentiation process.

For Peer Review

In this study, we aimed to characterize the Notch signaling pathway by analyzing the expression of all four Notch receptors, some ligands and the main nuclear target genes during the whole period of differentiation in MG63 cells, used as an *in vitro* cellular model of differentiation. During the osteoinductive treatment, MG63 showed the ability to differentiate, as shown by the increase in the production of early (ALP activity, Coll I) and later osteogenic markers (OC, matrix mineralization). Further, as expected, differentiation was associated to

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

the increased expression of known specific osteogenic transcription factors (Runx2, Dlx5, Osterix).

Interestingly, the analysis of the expression of Notch related genes has shown changes in the expression of specific Notch receptors and nuclear target genes at different times during differentiation, confirming the involvement of this pathway in the process. Specifically, in the osteoinductive condition a significant increase of Notch2 and Notch4 receptors was observed respect to untreated control cells in the later stage (days 21-28) of differentiation, whilst an underexpression of Notch1 and Notch3 receptors was found in the middle stage (days 7-14). These results are partially confirmed in literature. In fact, a reduced expression of Notch1 and Notch3 was previously reported by Zamurovic et al. (Zamurovic et al., 2004) in the osteogenic differentiation of MC3T3, a non-transformed mouse calvarial cell-line, induced by bone morphogenetic protein (BMP)-2, although the investigation was only until day 3. Viale-Bouroncle (Viale-Bouroncle et al., 2014) reported that Notch1 signaling regulates the BMP2/Dlx3 directed osteogenic differentiation of dental follicle cells via a negative feed-back loop, with a consequent reduction of ALP activity and mineralized nodules formation. Further, it has been reported that Notch1 maintained bone marrow mesenchymal progenitors in a stem-like state by suppressing Runx2 activity *in vitro* and *in vivo* (Hilton et al., 2008) and that the activity of Notch1 was suppressed during the induction of osteogenic differentiation, as manifested by the decreased expression of cleaved Notch1 and Hes1 (Li et al., 2014).

Although only few studies have investigated Notch2 and Notch4 receptors during osteogenic differentiation and none in our cellular model, however data reported in human alveolar bone-derived osteoprogenitor cells (Chakravorty et al., 2014) are in line with the increase of Notch2 and Notch4 expression found in our results.

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Our study, investigating all Notch receptors and Notch related genes during the whole period of osteogenic differentiation, appears to clarify and add new information indicating a complex involvement of Notch pathway in osteogenic differentiation with temporally dependent expression of specific genes. In particular, the increase in Notch 2 and Notch4 expression suggest that they are mainly involved in supporting differentiation, whilst the decrease in Notch1 and Notch3 expression seems to indicate a limited involvement of these two receptors in the progression of differentiation, confirming, at least partially, the role previously suggested for Notch1 in maintaining a stem-like state of the cells (Hilton et al., 2008).

Our data showed that the differences in Notch receptors expression were also related to specific changes in Notch nuclear target genes, further supporting the involvement of Notch pathway. Among the nuclear target genes, we found the upregulation of Hey1 (from day 7 until day 28) and the downregulation of Hes5 (at day 14-21) during differentiation. Notably, the increase of Hey1 expression was temporally associated with the enhancement of both early (ALP, Coll1) and late (osteocalcin, matrix mineralization) osteogenic markers, as well as of the known osteogenic transcription factors (Runx2, Dlx5, Osterix) expression, indicating a significant role for Hey1 during osteogenesis. A similar role of Hey1 has been also shown in other studies performed on mesenchymal stem cells and C2C12 cell line under BMP2 or BMP9 stimulation (de Jong et al., 2004; Sharff et al., 2009). However, in those studies Hey1 was investigated as a target gene modulated by BMPs stimulation. Differently, in our study Hey1 was investigated within Notch pathway, in association with the analysis of Notch receptors and ligands and its expression resulted increased during the whole differentiation process, also independently from the stimulation with BMPs.

Anyway, the correlation between Notch pathway and BMP signaling and the molecular mechanism behind the Hey1 functional role in osteogenesis remains to be defined, as controversial data have been previously reported. In fact, it has been proposed that Hey1 and

For Peer Review

Runx2 act synergistically in BMP9-induced osteogenic differentiation (de Jong et al., 2004; Sharff et al., 2009) but other authors found that Hey1 inhibited osteoblast maturation via interaction with Runx2 (Zamurovic et al., 2004). Our study, showing a temporally associated overexpression of both Hey1 and Runx2 from day 7 until day 28, appears to confirm a synergic role of these transcription factors in driving osteogenesis.

No previous data have been reported about Hes5 expression during osteogenic differentiation, however, findings in agreement with the trend found in our results have been reported in chondrogenic differentiation, showing a higher expression of Hes5 in dedifferentiated chondrocytes and a lower expression in differentiated cells, indicating that Hes5 may function as a negative regulator of cartilage differentiation in humans (Karlsson et al., 2007). Further, other pathways besides Notch can also be involved in Hes5 regulation, as it has been shown for Hes1 (Curry et al., 2006).

As the γ-secretase-mediated cleavage is the rate-limiting step of initiating Notch signaling, γ-secretase inhibitors, such as DAPT, have been frequently used as the effective research tools in uncovering novel functions of the Notch signaling. In the presence of DAPT, a decreased expression of the osteogenic markers as well as of Hey1 was observed. This indicates that the stimulation of Hey1, observed in our model, is induced by the activation of the canonical Notch pathway during osteogenic differentiation, reinforcing the link between Hey1 and osteogenic differentiation. Although data obtained in the presence of DAPT suggest that Notch signaling is directly involved in osteogenic differentiation, however, we cannot exclude cooperation between Notch and other pathways such as BMPs/Smads signaling.

Also, Western blotting analysis in DAPT confirmed the inhibition of the activation of Notch2 and Notch4, supporting the involvement of these receptors activation in inducing Hey1

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

expression. Accordingly, the activation of Hey1 downstream Notch2 and Notch4 has been previously reported in endothelial cells (Quillard et al., 2010, 2009).

Moreover, the absence of the active form of Notch1 and no change in the activated form of Notch3 in the absence and in the presence of DAPT, appear to suggest a minor role for these receptors. Anyway, we cannot exclude that these data could reflect the requirement for higher concentration of DAPT to inhibit the Notch receptors (1 and 3) involved in transcription of Hes5 (Chen et al., 2012). As with the progression of differentiation we observed an underexpression of Notch1, Notch3 and Hes5, we suggest that these genes may be mainly involved in maintaining cells in an undifferentiated status. Therefore, Notch pathway might be involved with a dual role in osteogenesis of MG63, with the induction of osteoblast formation through the activation of Notch2, Notch4 and Hey1 and, on the other hand, with the maintaining of an undifferentiated status through the depression of Notch1, Notch3 and Hes5.

In conclusion, the results obtained in this study show for the first time an involvement of Notch receptors and Hey1 in the promotion of osteogenic differentiation both in early and late phases of the process. The induction of Hey1 might act through the modulation of the key transcription factors which are known to drive osteogenesis. The increase of knowledge in major signaling pathways which contribute to regulate osteogenesis is of great relevance. In clinics, the ability to manipulate osteogenesis has far-reaching clinical potential for pathological conditions such as osteoporosis, osteogenesis imperfecta, osteolytic lesions in metastatic cancers, primary bone tumors and bone regeneration.

For Peer Review

Conflict of Interest

The Authors state that they have no conflicts of interest.

Authorship

1
2
3 AO, Study conception and design, data analysis and interpretation, drafting manuscript,
4
5 approving final version and submission of the manuscript; AP, LB, CC, data collection, data
6
7 analysis, revising manuscript content, approving final version of the manuscript; PR, data
8
9 analysis and interpretation, revising manuscript content, approving final version of the
10
11 manuscript; LM, revising manuscript content, approving final version of the manuscript;
12
13 MDM, data interpretation, discussing and revising manuscript content, approving final
14
15 version of the manuscript.
16
17
18
19 **REFERENCES**
20
21

22 Bai S, Kopan R, Zou W, Hilton MJ, Ong C, Long F, Ross FP, Teitelbaum SL. 2008.
23 NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly
24 via osteoblast lineage cells. J Biol Chem 283:6509–6518.
25 Bray SJ. 2006. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol
26 7:678–689.
27 Caliceti C, Aquila G, Pannella M, Morelli MB, Fortini C, Pinton P, Bonora M, Hrelia S,
28 Pannuti A, Miele L, Rizzo P, Ferrari R. 2013. 17β-estradiol enhances signalling
29 mediated by VEGF-A-delta-like ligand 4-notch1 axis in human endothelial cells. PloS
30 One 8:e71440.
31 Chakravorty N, Hamlet S, Jaiprakash A, Crawford R, Oloyede A, Alfarsi M, Xiao Y,
32 Ivanovski S. 2014. Pro-osteogenic topographical cues promote early activation of
33 osteoprogenitor differentiation via enhanced TGFβ, Wnt, and Notch signaling. Clin
34 Oral Implants Res 25:475–486.
35 Chen S, Lee BH, Bae Y. 2014. Notch signaling in skeletal stem cells. Calcif Tissue Int 94:
36 68–77.
37 Chen Y, Zheng S, Qi D, Zheng S, Guo J, Zhang S, Weng Z. 2012. Inhibition of Notch
38 signaling by a γ-secretase inhibitor attenuates hepatic fibrosis in rats. PloS One
39 7:e46512.
40 Curry CL, Reed LL, Nickoloff BJ, Miele L, Foreman KE. 2006. Notch-independent
41 regulation of Hes-1 expression by c-Jun N-terminal kinase signaling in human
42 endothelial cells. Lab Investig J Tech Methods Pathol 86:842–852.
43 de Jong DS, Steegenga WT, Hendriks JMA, van Zoelen EJJ, Olijve W, Dechering KJ. 2004.
44 Regulation of Notch signaling genes during BMP2-induced differentiation of
45 osteoblast precursor cells. Biochem Biophys Res Commun 320:100–107.
46 Deng Z-L, Sharff KA, Tang N, Song W-X, Luo J, Luo X, Chen J, Bennett E, Reid R,
47 Manning D, Xue A, Montag AG, Luu HH, Haydon RC, He T-C. 2008. Regulation of
48 osteogenic differentiation during skeletal development. Front Biosci J Virtual Libr 13:
49 2001–2021.
50 Deregowski V, Gazzerro E, Priest L, Rydziel S, Canalis E. 2006. Notch 1 overexpression
51 inhibits osteoblastogenesis by suppressing Wnt/beta-catenin but not bone
52 morphogenetic protein signaling. J Biol Chem 281:6203–6210.
53 Ducy P, Schinke T, Karsenty G. 2000. The osteoblast: a sophisticated fibroblast under central
54 surveillance. Science 289:1501–1504.

55
56
57
58
59
60

For Peer Review

1
2
3 Groot AJ, Habets R, Yahyanejad S, Hodin CM, Reiss K, Saftig P, Theys J, Vooijs M. 2014. Regulated proteolysis of NOTCH2 and NOTCH3 receptors by ADAM10 and presenilins. Mol Cell Biol 34:2822–2832.
Hilton MJ, Tu X, Wu X, Bai S, Zhao H, Kobayashi T, Kronenberg HM, Teitelbaum SL, Ross FP, Kopan R, Long F. 2008. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med 14:306–314.
Iso T, Kedes L, Hamamori Y. 2003. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 194: 237–255.
Karlsson C, Jonsson M, Asp J, Brantsing C, Kageyama R, Lindahl A. 2007. Notch and HES5 are regulated during human cartilage differentiation. Cell Tissue Res 327:539–551.
Komori T. 2010. Regulation of osteoblast differentiation by Runx2. Adv Exp Med Biol 658: 43–49.
Komori T. 2006. Regulation of osteoblast differentiation by transcription factors. J Cell Biochem 99:1233–1239.
Kraus D, Deschner J, Jäger A, Wenghoefer M, Bayer S, Jepsen S, Allam JP, Novak N, Meyer R, Winter J. 2012. Human β-defensins differently affect proliferation, differentiation, and mineralization of osteoblast-like MG63 cells. J Cell Physiol 227:994–1003.
Li Y, Li J, Zhuang W, Wang Q, Ge X, Zhang X, Chen P, Fu J, Li B. 2014. Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro. Leuk Res 38:970–976.
Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B. 2002. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108:17–29.
Nobta M, Tsukazaki T, Shibata Y, Xin C, Moriishi T, Sakano S, Shindo H, Yamaguchi A. 2005. Critical regulation of bone morphogenetic protein-induced osteoblastic differentiation by Delta1/Jagged1-activated Notch1 signaling. J Biol Chem 280:15842–15848.
Ongaro A, Pellati A, Bagheri L, Fortini C, Setti S, De Mattei M. 2014. Pulsed electromagnetic fields stimulate osteogenic differentiation in human bone marrow and adipose tissue derived mesenchymal stem cells. Bioelectromagnetics 35:426–436.
Quillard T, Devalliere J, Chatelais M, Coulon F, Séveno C, Romagnoli M, Barillé Nion S, Charreau B. 2009. Notch2 signaling sensitizes endothelial cells to apoptosis by negatively regulating the key protective molecule survivin. PloS One 4:e8244.
Quillard T, Devallière J, Coupel S, Charreau B. 2010. Inflammation dysregulates Notch signaling in endothelial cells: implication of Notch2 and Notch4 to endothelial dysfunction. Biochem Pharmacol 80:2032–2041.
Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, Selvaggi S, Bashir A, Bhandari D, Marchese A, Lendahl U, Qin J-Z, Tonetti DA, Albain K, Nickoloff BJ, Miele L. 2008. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 68:5226–5235.
Sciaudone M, Gazzerro E, Priest L, Delany AM, Canalis E. 2003. Notch 1 impairs osteoblastic cell differentiation. Endocrinology 144:5631–5639.
Sharff KA, Song W-X, Luo X, Tang N, Luo J, Chen J, Bi Y, He B-C, Huang J, Li X, Jiang W, Zhu G-H, Su Y, He Y, Shen J, Wang Y, Chen L, Zuo G-W, Liu B, Pan X, Reid RR, Luu HH, Haydon RC, He T-C. 2009. Hey1 basic helix-loop-helix protein plays an important role in mediating BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. J Biol Chem 284:649–659.
Shimizu T, Tanaka T, Iso T, Doi H, Sato, H, Kawai-Kowase K, Arai M, Kurabayashi M. 2009. Notch signaling induces oseogenic differentiation and mineralization of vascular

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

smooth muscle cells: role of Msx2 gene induction via Notch-RBP-Jk signaling. Arterioscler Thromb Vasc Biol 29:1104–1111.
Tezuka K-I, Yasuda M, Watanabe N, Morimura N, Kuroda K, Miyatani S, Hozumi N. 2002. Stimulation of osteoblastic cell differentiation by Notch. J Bone Miner Res Off J Am Soc Bone Miner Res 17:231–239.
Viale-Bouroncle S, Gosau M, Morsczeck C. 2014. NOTCH1 signaling regulates the BMP2/DLX-3 directed osteogenic differentiation of dental follicle cells. Biochem Biophys Res Commun 443:500–504.
Zamurovic N, Cappellen D, Rohner D, Susa M. 2004. Coordinated activation of notch, Wnt, and transforming growth factor-beta signaling pathways in bone morphogenic protein 2-induced osteogenesis. Notch target gene Hey1 inhibits mineralization and Runx2 transcriptional activity. J Biol Chem 279:37704–37715.
Zanotti S, Smerdel-Ramoya A, Stadmeyer L, Durant D, Radtke F, Canalis E. 2008. Notch inhibits osteoblast differentiation and causes osteopenia. Endocrinology 149:3890–3899.

For Peer Review

FIGURE LEGENDS

Figure 1. Biochemical markers during osteogenic differentiation of MG63 cells. Cells were cultured in DMEM/F12 (control, white bar) or in OM (grey bar) for 28 days. At different time points (1, 3, 7, 14, 21, 28) cells were tested for ALP activity (A), osteocalcin levels (B) and matrix mineralization by Alizarin red (C). The quantification of Alizarin red staining was done spectrophotometrically and reported in the graph under the panel. To verify if the changes observed in OM were due to differences in cell number, cell proliferation was evaluated both in control and in OM treated cells (D). *Statistical significance versus control, at the corresponding time point.

Figure 2. Expression of osteogenic transcription factors Runx2 (A), Dlx5 (B), Osterix (C) and expression of collagene type I (D) in MG 63 at different times during osteogenic differentiation. Cells were cultured in DMEM/F12 (control, white bar) or in OM (grey bar) for 28 days. *Statistical significance versus control, at the corresponding time point.

Figure 3. Expression of Notch receptors and nuclear target genes in MG63 at different times during osteogenic differentiation. Cells were cultured in DMEM/F12 (control, white bar) or in OM (grey bar) for 28 days. (A) Notch1 receptor; (B) Notch2 receptor; (C) Notch3 receptor;

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(D) Notch4 receptor; (E) Hey1; (F) Hes5. *Statistical significance versus control, at the corresponding time point.

Figure 4. Effects of DAPT treatment on osteogenic biochemical markers and cell proliferation in MG63 at different times during osteogenic differentiation. Cells were cultured in OM (grey bar) or in OM+DAPT (black bar) for 28 days. The presence of DAPT in OM reduced ALP activity (A), osteocalcin levels (B) and matrix mineralization, quantified spectrophotometrically through the dissolution of Alizarin red staining (C). DAPT did not influence cell proliferation (D). °Statistical significance versus OM, at the corresponding time point.

Figure 5. Effects of DAPT treatment on osteogenic transcription factors Runx2 (A), Dlx5 (B), Osterix (C) and on collagene type I (D) in MG63 at different times during osteogenic differentiation. Cells were cultured in OM (grey bar) or in OM+DAPT (black bar) for 28 days. °Statistical significance versus OM, at the corresponding time point.

Figure 6. Effects of DAPT treatment on Hey1 in MG63 at different times during osteogenic differentiation. Cells were cultured in OM (grey bar) or in OM+DAPT (black bar) for 28 days. DAPT significantly inhibited Hey1 expression at all differentiation times investigated. °Statistical significance versus OM, at the corresponding time point.

Figure 7. Effects of DAPT treatment on Notch receptors in MG63 at day 21 during osteogenic differentiation. MG63 were cultured in OM and in OM+DAPT (OM+D) until day 21. Cell lysates were electrophoresed and immunoblotted with antibody for Notch1, Notch2, Notch3, Notch4. β-actin antibody was used to ensure equal loading. The panel shows, for each Notch receptor, the full-length (FL) precursor, the transmembrane (TM) and/or intracellular (IC) fragment. Extracellular truncation cleavage fragments were present for Notch2 (N2EXT), and for Notch3 (N3EXT), as described in the Results section.

For Peer Review



Figure 1. Biochemical markers during osteogenic differentiation of MG63 cells. Cells were cultured in DMEM/F12 (control, white bar) or in OM (grey bar) for 28 days. At different time points (1, 3, 7, 14, 21, 28) cells were tested for ALP activity (A), osteocalcin levels (B) and matrix mineralization by Alizarin red (C). The quantification of Alizarin red staining was done spectrophotometrically and reported in the graph under the panel. To verify if the changes observed in OM were due to differences in cell number, cell proliferation was evaluated both in control and in OM treated cells (D). *Statistical significance versus control, at the corresponding time point.
130x96mm (300 x 300 DPI)



Figure 2. Expression of osteogenic transcription factors Runx2 (A), Dlx5 (B), Osterix (C) and expression of collagene type I (D) in MG 63 at different times during osteogenic differentiation. Cells were cultured in DMEM/F12 (control, white bar) or in OM (grey bar) for 28 days. *Statistical significance versus control, at the corresponding time point.
121x83mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40



41
42
43
44
45

Figure 3. Expression of Notch receptors and nuclear target genes in MG63 at different times during osteogenic differentiation. Cells were cultured in DMEM/F12 (control, white bar) or in OM (grey bar) for 28 days. (A) Notch1 receptor; (B) Notch2 receptor; (C) Notch3 receptor; (D) Notch4 receptor; (E) Hey1; (F) Hes5. *Statistical significance versus control, at the corresponding time point.
182x188mm (300 x 300 DPI)

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 4. Effects of DAPT treatment on osteogenic biochemical markers and cell proliferation in MG63 at different times during osteogenic differentiation. Cells were cultured in OM (grey bar) or in OM+DAPT (black bar) for 28 days. The presence of DAPT in OM reduced ALP activity (A), osteocalcin levels (B) and matrix mineralization, quantified spectrophotometrically through the dissolution of Alizarin red staining (C). DAPT did not influence cell proliferation (D). °Statistical significance versus OM, at the corresponding time point.
123x85mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 5. Effects of DAPT treatment on osteogenic transcription factors Runx2 (A), Dlx5 (B), Osterix (C) and on collagene type I (D) in MG63 at different times during osteogenic differentiation. Cells were cultured in OM (grey bar) or in OM+ DAPT (black bar) for 28 days. °Statistical significance versus OM, at the corresponding time point.
121x82mm (300 x 300 DPI)

Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 6. Effects of DAPT treatment on Hey1 in MG63 at different times during osteogenic differentiation. Cells were cultured in OM (grey bar) or in OM+DAPT (black bar) for 28 days. DAPT significantly inhibited Hey1 expression at all differentiation times investigated. °Statistical significance versus OM, at the corresponding time point.
57x39mm (300 x 300 DPI)

Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 7. Effects of DAPT treatment on Notch receptors in MG63 at day 21 during osteogenic differentiation. MG63 were cultured in OM and in OM+DAPT (OM+D) until day 21. Cell lysates were electrophoresed and immunoblotted with antibody for Notch1, Notch2, Notch3, Notch4. β-actin antibody was used to ensure equal loading. The panel shows, for each Notch receptor, the full-length (FL) precursor, the transmembrane (TM) and/or intracellular (IC) fragment. Extracellular truncation cleavage fragments were present for Notch2 (N2EXT), and for Notch3 (N3EXT), as described in the Results section.
100x120mm (600 x 600 DPI)